Stent material for promoting vascularized bone tissue regeneration and preparation method thereof

By introducing gentiopicroside into the biological scaffold material, the problem of insufficient vascularization of the biological scaffold material in bone defect repair was solved, achieving efficient, safe and economical bone tissue regeneration, and overcoming the shortcomings of traditional growth factor therapy.

CN121059892APending Publication Date: 2025-12-05SHENZHEN INST OF ADVANCED TECH +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511077027.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-01
Publication Date
2025-12-05

AI Technical Summary

Technical Problem

Existing biological scaffold materials lack effective vascularization function in bone defect repair, resulting in insufficient osteogenic activity, which prolongs the tissue regeneration and repair time. Furthermore, traditional growth factor therapies are costly, have poor stability, and pose risks of side effects.

Method used

By modifying bio-scaffold materials with gentianin, a small molecule active ingredient from traditional Chinese medicine, and preparing porous scaffolds using 3D printing and freeze-drying technology, we can significantly promote angiogenesis during bone repair and avoid dependence on expensive and unstable growth factors.

Benefits of technology

It significantly improves bone repair efficiency, shortens tissue regeneration cycle, reduces treatment costs, avoids side effect risks, and provides a safe, efficient, and economical vascularized bone regeneration solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121059892A_ABST
    Figure CN121059892A_ABST
Patent Text Reader

Abstract

The invention provides a scaffold material for promoting vascularized bone tissue regeneration and a preparation method thereof, the scaffold material for promoting vascularized bone tissue regeneration is a biological scaffold material based on traditional Chinese medicine active micromolecule gentiopicroside modification, and aims to solve the problem that the biological scaffold material in bone repair is insufficient in vascular regeneration capacity. The core of the strategy is that the GPD is utilized to modify the biological scaffold, and the revascularization in the bone repair process is remarkably promoted, so that the dependence on poor-stability and expensive vascular growth factors (such as VEGF (vascular endothelial growth factor), PDGF-BB (PDGF-BB) and the like) is avoided. Therefore, the gentiopicroside shows a huge application prospect in the field of bone repair, especially in the aspect of large-area bone defect vascular regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the field of biomedical tissue engineering, and particularly relates to a scaffold material for promoting vascularized bone tissue regeneration and a preparation method thereof. BACKGROUND

[0002] Various types of bone defects caused by trauma, fracture combined with infection, bone tumor resection, congenital deformity and other factors are very common clinical conditions, and the treatment and repair of large-scale and large-area bone defects are common problems faced by bone surgery, craniofacial surgery and plastic surgery. The number of bone defect patients worldwide is in the tens of millions each year, and the number of patients requiring bone transplantation surgery exceeds 2 million. In China, the number of bone defect patients exceeds 5 million each year, and the number of bone defect patients is increasing year by year. The high incidence of bone defects has made bone grafts become the second largest medical demand consumables after blood transfusion, causing a heavy medical burden to society. Therefore, the repair of bone diseases, especially large-area bone damage, has become one of the most important medical needs in China.

[0003] Traditional methods for treating bone defects include autologous bone transplantation and allogeneic bone transplantation. Autologous bone transplantation is generally considered the "gold standard" for treating bone defects due to its high safety and strong bone induction. However, it is greatly limited in application due to limited bone supply, difficulty in obtaining materials, and postoperative complications. However, both autologous bone transplantation and allogeneic bone transplantation have their own insurmountable drawbacks and cannot meet the clinical needs.

[0004] Biological scaffold materials are an effective strategy to repair large-area bone defects, a difficult problem in orthopedics. In the past few decades, natural or artificially synthesized degradable polymer scaffolds have shown good efficacy in bone defect repair. However, despite having some repair capabilities, such materials often lack effective vascularization function, leading to insufficient bone formation activity in the defect area, limiting their effectiveness in bone regeneration and repair, prolonging the time of tissue regeneration and repair, and being detrimental to patient recovery.

[0005] In order to improve the vascular regeneration capacity of biological scaffolds and thus improve the efficiency of bone repair, the conventional approach is to integrate growth factors with pro-angiogenic effects (such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF), angiopoietin (Ang), platelet-derived growth factor-BB (PDGF-BB), transforming growth factor-β1 (TGF-β1), etc.) into the scaffold material through physical or chemical methods to enhance vascular regeneration and promote bone repair.

[0006] Although the bio-scaffolds of integrated growth factors show potential in promoting vascularization and bone repair, their clinical application is limited by a series of key drawbacks: first, the high production cost makes the growth factor-based therapy extremely expensive, greatly increasing the medical burden; second, the extremely short biological half-life in vivo leads to rapid loss of activity, making it difficult to maintain a persistent pro-angiogenic effect, often requiring repeated administration or an ultra-high initial dose, which in turn is extremely prone to cause significant side effects, such as pathological vascular proliferation, local inflammatory response and even systemic adverse reactions; third, in terms of scaffold loading technology, the physical adsorption method cannot avoid the burst release of high-concentration growth factors at the initial stage of implantation (burst effect), resulting in excessive local concentration and low utilization rate, while the chemical fixation strategy may destroy the fine spatial conformation, leading to partial or complete loss of biological activity; finally, bone repair and vascularization are highly spatiotemporal coordinated complex processes, and the effect of a single growth factor is limited, while accurately simulating the physiological synergistic release of multiple factors (such as VEGF, PDGF, bFGF, etc.) at a specific time window and spatial location is technically challenging and costly. These deep-seated defects jointly constrain the clinical efficacy, safety and wide accessibility of growth factor scaffolds. SUMMARY

[0007] The present application provides a small molecule Gentiopicroside (GPD) derived from active ingredients of traditional Chinese medicine as a promoter of vascular regeneration, for enhancing the vascular regeneration ability of bio-scaffold materials in the process of repairing bone defects, and improving the bone repair efficiency.

[0008] To achieve the above object, the technical scheme adopted by the present application is as follows:

[0009] The present application provides a preparation method of a scaffold material for promoting vascularized bone tissue regeneration, which comprises: dissolving Gentiopicroside in an organic solvent to obtain a Gentiopicroside solution; dissolving a bio-scaffold material in an organic solvent to obtain a bio-scaffold material solution; adding the Gentiopicroside solution to the bio-scaffold material solution, stirring uniformly to obtain a scaffold solution for printing; 3D printing the scaffold solution for printing to obtain a porous scaffold crude product; and sequentially performing freeze-drying and organic solvent removal on the porous scaffold crude product to obtain the scaffold material for promoting vascularized bone tissue regeneration.

[0010] Further, the material of the bio-scaffold material includes biodegradable high molecular material and hydrogel material; wherein the biodegradable high molecular material includes poly-3-hydroxybutyrate-co-4-hydroxybutyric acid ester, polyhydroxybutyric acid ester, polyhydroxybutyric acid pentyl ester, polyglycolide, polylactic acid or polyhydroxyalkanoic acid ester material of polycaprolactone; and the hydrogel material includes sodium alginate, agarose, collagen, polyethylene glycol, polyacrylamide or poly N-isopropyl acrylamide.

[0011] Further, the organic solvent includes chloroform, dichloromethane, 1,4 dioxane or dimethyl sulfoxide.

[0012] Further, the freeze-drying operation includes freeze-drying treatment for 48h in a vacuum drying manner.

[0013] Further, the preparation method specifically includes: dissolving 0.15g-0.3g of gentiopicroside in 1.0mL of chloroform to obtain a gentiopicroside solution; then adding the gentiopicroside solution into 10g of poly-3-hydroxybutyrate-co-4-hydroxybutyrate solution which has been fully dissolved in 20mL of chloroform; magnetically stirring at room temperature for 1h to form a uniform solution, and then printing by using a biological 3D printer to obtain a porous scaffold crude product; placing the porous scaffold crude product in a vacuum drying machine for freeze-drying for 48h to remove chloroform, and obtaining a GPD@P34HB porous scaffold with a content.

[0014] The application further provides a scaffold material for promoting vascularized bone tissue regeneration prepared by the preparation method of the scaffold material for promoting vascularized bone tissue regeneration.

[0015] The application further provides application of gentiopicroside as a blood vessel regeneration promoter in the field of biological scaffold material preparation.

[0016] The application further provides application of gentiopicroside as a drug in the field of blood vessel regeneration promotion.

[0017] Further, the application includes: placing 0.356g of gentiopicroside in a centrifugal tube, adding 1.0mL of dimethyl sulfoxide solution into the centrifugal tube, oscillating on a vortexer for 5min to fully dissolve the gentiopicroside, then adding the obtained solution dropwise into 9.0mL of double-distilled water, and filtering by using a 0.22μm filter membrane to configure a storage mother liquor with a concentration of 100mM; taking the mother liquor to configure human umbilical vein vascular endothelial cell DMEM complete culture medium containing gentiopicroside with concentrations of 0, 0.32, 0.64, 1.28 and 2.56mM respectively.

[0018] The application further provides application of gentiopicroside as a therapeutic drug in improving insufficient blood vessel regeneration and related diseases.

[0019] Compared with the prior art, the technical scheme provided by the application has at least the following advantages:

[0020] The application provides a scaffold material for promoting vascularized bone tissue regeneration and a preparation method thereof. The application uses gentiopicroside to replace traditional growth factors, because gentiopicroside has the advantages of wide natural sources, low cost, stable chemical properties, excellent biocompatibility and extremely low risk of side effects. The replacement fundamentally solves the core problems in the clinical application of traditional growth factors, i.e., high cost, in-vivo degradation and inactivation and potential side effects (such as abnormal blood vessel proliferation). This opens up a new technical path for developing safe, efficient and economical vascularized bone regeneration biological scaffold materials, and has great scientific value and broad clinical application prospect in the field of bone tissue engineering.

[0021] In addition to being used for blood vessel regeneration in the process of tissue and organ regeneration and repair in combination with a biological scaffold, the gentiopicroside provided by the application can be used as a therapeutic drug to improve diseases related to insufficient blood vessel regeneration, such as the reduction of internal blood vessels of bone tissue caused by osteoporosis and the blood vessel regeneration barrier problem existing in diabetic foot ulcers. BRIEF DESCRIPTION OF DRAWINGS

[0022] One or more embodiments are illustrated by way of example in the accompanying drawings that are not intended to be limiting of the embodiments so far as they may depart from the prior art, unless otherwise expressly indicated, the drawings in which:

[0023] Figure 1 is a flow chart of an experiment of gentiopicroside for promoting vascularized bone regeneration provided by an embodiment of the application;

[0024] Figure 2 is CCK-8 test of the proliferation effect of gentiopicroside on Ea.hy926 cells provided by an embodiment of the application;

[0025] Figure 3 is gentiopicroside for promoting Ea.hy926 cell migration provided by an embodiment of the application;

[0026] Figure 4 is gentiopicroside for promoting Ea.hy926 cell microvessel network formation and quantitative analysis provided by an embodiment of the application;

[0027] Figure 5 is 3D biological printing preparation of a porous scaffold containing different concentrations of gentiopicroside provided by an embodiment of the application;

[0028] Figure 6 is a mouse subcutaneous transplantation of a porous scaffold containing different concentrations of gentiopicroside for promoting blood vessel regeneration provided by an embodiment of the application;

[0029] Figure 7 is a porous scaffold modified by gentiopicroside for promoting blood vessel regeneration and quantitative analysis of blood vessel density at a bone defect site provided by an embodiment of the application;

[0030] Figure 8 The gypenoside modified porous scaffold promotes vascularized bone regeneration provided by the embodiments of the present application. DETAILED DESCRIPTION

[0031] Based on the background art, the current regeneration and repair of large bone defects is a major challenge in clinical practice, mainly due to its poor vascular regeneration and osteogenesis ability. In order to accelerate the repair process, bone grafts are often used to fill the defect site to guide bone tissue regeneration. High molecular weight biological scaffold materials, such as poly-3-hydroxybutyrate-4-hydroxybutyrate (P34HB), polyglycolide (PLGA), polylactic acid (PLA), polycaprolactone (PCL), etc., have been widely used in such repairs due to their good biocompatibility and biodegradability. However, these high molecular weight scaffold materials generally have a key defect: lack of effective induction of vascular regeneration or insufficient vascularization potential. This directly leads to a significant prolongation of the time required to repair large bone defects using these materials, and more seriously, necrosis may occur in the interior of the graft due to long-term ischemia. Successful bone repair is highly dependent on the ordered cooperation of bone regeneration and angiogenesis, which is a process precisely regulated by a complex signal network. Among them, the early formation of the vascular network is a prerequisite and core guarantee for bone regeneration - it timely transports essential oxygen, nutrients for new bone formation, and ensures the effective discharge of metabolic waste. Therefore, to achieve efficient regeneration and functional reconstruction of large bone defects, it is imperative to establish a perfect vascular network between the bone graft and the host tissue as soon as possible. The present application provides a biological scaffold material modified with the active small molecule gypenoside based on traditional Chinese medicine, aiming to solve the problem of insufficient vascular regeneration of biological scaffold materials in bone repair. The core of this strategy is to use GPD to modify the biological scaffold, significantly promoting vascular regeneration during bone repair, thereby avoiding the dependence on stable and expensive vascular growth factors (such as VEGF, PDGF-BB, etc.). Therefore, gypenoside has great application prospects in the field of bone repair, especially in the vascular regeneration of large bone defects.

[0032] In order to completely overcome the inherent defects of growth factors in the prior art, the core innovation of the present application lies in the groundbreaking selection of the active small molecule of traditional Chinese medicine, gentiopicroside, as a high-efficiency and safe blood vessel regeneration promoter. The fundamental purpose of using GPD to modify the biological scaffold material is: 1) to avoid high cost: using a natural product with wide sources and low cost to replace expensive recombinant growth factors, significantly reducing treatment costs; 2) to solve the stability problem: taking advantage of the excellent chemical stability of GPD, overcoming the bottleneck of in vivo degradation and storage difficulties of growth factors, and ensuring long-term effect; 3) to eliminate safety risks: using its excellent biocompatibility and extremely low side effect risk, avoiding abnormal vascular proliferation, inflammation and other adverse reactions caused by high dose or burst release; 4) to simplify the regulation strategy: as a single small molecule, it can effectively promote the formation of functional vascular network, bypassing the stringent technical requirements for precise control of complex multi-factor space-time cooperation. Therefore, the use of GPD instead of growth factors is not just a simple component replacement, but a major paradigm shift in vascularized bone regeneration strategy. With its comprehensive advantages of economy of natural sources, stability at the molecular level, high efficiency of biological utilization, and safety in clinical application, GPD lays the foundation for the development of a new generation of "safe-high efficiency-economy" three-in-one vascularized bone regeneration scaffold. This not only significantly improves the efficiency and reliability of bone defect repair, shortens the tissue regeneration cycle, but also greatly promotes the substantial transformation of bone tissue engineering products from the laboratory to the clinic, with scientific value and application prospect.

[0033] The present application will be described in detail below in conjunction with specific embodiments.

[0034] Embodiments

[0035] The present application provides a scaffold material for promoting vascularized bone tissue regeneration and a preparation method thereof, as shown in Figure 1 The preparation method comprises:

[0036] ① Weigh 0.356 g of gentiopicroside and place it in a 1 mL centrifuge tube. Add 1.0 mL of dimethyl sulfoxide solution to the centrifuge tube, shake on a vortex for 5 minutes to dissolve the GPD, then add the above solution to 9.0 mL of double distilled water, and filter with a 0.22 μm filter membrane to obtain a storage mother liquor with a concentration of 100 mM.

[0037] ② Take an appropriate volume of the above mother liquor to prepare DMEM complete culture medium containing GPD at concentrations of 0, 0.32, 0.64, 1.28, and 2.56 mM.

[0038] ③ The proliferation toxicity of the above DMEM complete culture medium with GPD at different concentrations on EA.Hy926 cells was detected by CCK-8, as shown in Figure 2 Figure 2 ​It can be seen that Gentiopicroside promotes the proliferation of EA.Hy926 cells, showing good cell biocompatibility.

[0039] ④Taking GPD concentrations of 0, 1.28, 2.56 mM as examples, the effect of GPD on the migration of EA.Hy926 cells was detected, as shown in Figure 3 Figure 3 A in the middle is the crystal violet staining of Ea.hy926 cells cultured in Transwell for 48 h; B is the quantitative analysis of the number of Ea.hy926 cell migration; C is the scratch of Ea.hy926 cells; D is the quantitative analysis of Ea.hy926 cells. From Figure 3 It can be seen that Gentiopicroside can significantly promote the migration of EA.Hy926 cells, which is conducive to wound regeneration and healing.

[0040] ⑤Taking GPD concentrations of 0, 1.28, 2.56 mM as examples, the effect of GPD on the migration of EA.Hy926 cells was detected, as shown in Figure 4 Figure 4 A in the middle is the crystal violet staining of Ea.hy926 cells cultured in Transwell for 48 h; B is the quantitative analysis of the number of Ea.hy926 cell migration; C is the scratch of Ea.hy926 cells; D is the quantitative analysis of Ea.hy926 cells. From

[0041] ⑥On the basis of the above experiments, GPD with good biocompatibility and the function of promoting blood vessel regeneration was modified to degradable poly-3-hydroxybutyrate-co-4-hydroxybutyric acid (P34HB) biological scaffold material. The specific steps are as follows: 0.15 g of GPD is dissolved in 1.0 mL of chloroform, and then the GPD solution is added to a 10 g P34HB solution that has been fully dissolved in 20 mL of chloroform. Stir for 1 hour at room temperature to form a uniform solution, then use a biological 3D printer to prepare a GPD@P34HB porous scaffold with a GPD content of 1.5 wt%, and then place the porous scaffold in a vacuum drying machine for freeze-drying for 48 h to remove the organic solvent chloroform, obtaining a GPD@P34HB porous scaffold with a content of 1.5 wt%.

[0042] GPD@P34HB with a content of 3 wt% and blank control P34HB porous scaffold are prepared according to the above method, as shown in Figure 5

[0043] ⑦The above P34HB, 1.5 wt% GPD@P34HB, 3 wt% GPD@P34HB porous scaffolds were respectively transplanted into the subcutaneous tissue of C57BL mice, and after 2 weeks, the vascular regeneration was observed, as shown in Figure 6 Figure 6 It can be seen that Gentiopicroside can promote vascular regeneration in vivo, which is conducive to the repair of vascularized tissue.

[0044] ​​​​8. The P34HB, 1.5wt% GPD@P34HB, and 3wt% GPD@P34HB porous scaffolds were transplanted into the rat skull defect (5mm) sites, respectively, and the bone defect sites without any treatment were used as a blank control group.

[0045] 9. After 8 weeks of scaffold transplantation, two-photon excitation fluorescence (TPEF) technology was used to image the blood vessels in the rat bone defect area. Before imaging, the rats were anesthetized by inhaling 3.5% isoflurane. To obtain high-quality, high signal-to-noise ratio images of new blood vessels, 2mg fluorescein isothiocyanate (FITC) labeled dextran (molecular weight 250KD) was injected into the rat tail vein. Multiple uniformly distributed sampling points were selected in the bone defect area for blood vessel imaging, with an imaging depth interval of 2 microns, as shown in Figure 7 Figure 7 Figure 8 shows that the gypenoside-modified porous scaffold significantly promotes vascular regeneration in the bone defect site. Figure 7

[0046] 10. After the above blood vessel imaging data collection was completed, small animal CT imaging was used to detect and evaluate the bone regeneration and repair in the bone defect area, as shown in Figure 8 Figure 8 Figure 9 shows that the gypenoside-modified porous scaffold significantly promotes the vascularization coupling of the bone regeneration process and accelerates the vascularized bone tissue regeneration and repair. Figure 8

[0047] At the end of the experiment, samples were collected, and then histological staining was performed to evaluate the vascularized bone regeneration.

[0048] ​​​​In summary, the application innovatively proposes to use the active small molecule compound gypenoside from traditional Chinese medicine as the core of the blood vessel regeneration promoter to solve the key bottleneck of insufficient vascularization of the current biological stent material in bone defect repair. Unlike the conventional strategy of relying on expensive and unstable growth factors (such as VEGF, bFGF, etc.), the application stably modifies and integrates GPD on the biological stent material through physical adsorption or chemical bonding. This GPD functionalized stent can continuously and effectively stimulate and enhance local angiogenesis after being implanted in the bone defect site, significantly accelerating the establishment of functional vascular networks inside the stent and their effective integration with the surrounding tissues of the host. This process greatly optimizes the microenvironment inside the stent, providing essential nutritional support and metabolic basis for subsequent osteoblast migration, proliferation, and differentiation, as well as efficient bone tissue regeneration. What is particularly important is that the core breakthrough of the application is the successful replacement of traditional growth factors with GPD, which fundamentally avoids the inherent defects of the latter in clinical applications, such as high cost, in vivo degradation and inactivation, potential side effects (such as abnormal vascular proliferation, inflammatory response), burst effect, and difficulty in multi-factor synergistic regulation. GPD, with its significant advantages of wide natural sources, low cost, stable chemical properties, excellent biocompatibility, and extremely low risk of side effects, opens up a new technical path for the development of safe, efficient, and economical vascularized bone regeneration biological stent material, and has great scientific significance and broad clinical application prospects in the field of bone tissue engineering.

[0049] Those skilled in the art can understand that the above-mentioned embodiments are specific examples for implementing the application, and in actual application, various changes can be made in form and details without departing from the spirit and scope of the application. Any person skilled in the art can make respective changes and modifications without departing from the spirit and scope of the application, therefore the protection scope of the application should be limited by the scope defined in the claims.

Claims

1. A method for preparing a scaffold material for promoting vascularized bone tissue regeneration, characterized by, The preparation method comprises the following steps: dissolving gentiopicroside in an organic solvent to obtain a gentiopicroside solution; dissolving a biological scaffold material in an organic solvent to obtain a biological scaffold material solution; adding the gentiopicroside solution into the biological scaffold material solution, and stirring uniformly to obtain a scaffold solution for printing; performing 3D printing on the scaffold solution for printing to obtain a porous scaffold crude product; and sequentially performing freeze-drying and organic solvent removal on the porous scaffold crude product to obtain the scaffold material for promoting blood vesselization and bone tissue regeneration.

2. The method of claim 1, wherein the scaffold material is prepared by the steps of: a) mixing the biocompatible polymer and the bioactive agent; b) dissolving the mixture in a solvent; c) removing the solvent; and d) drying the mixture. The material of the biological scaffold material comprises a biodegradable polymer material and a hydrogel material. The biodegradable polymer material comprises poly-3-hydroxybutyrate-co-4-hydroxybutyrate, polyhydroxybutyrate, polyhydroxyvalerate, polyglycolide, polylactic acid or polyhydroxyalkanoate materials such as polycaprolactone; and the hydrogel material comprises sodium alginate, agarose, collagen, polyethylene glycol, polyacrylamide or poly-N-isopropyl acrylamide.

3. The method of claim 1, wherein the scaffold material is prepared by the steps of: a) mixing the biocompatible polymer and the bioactive agent; b) dissolving the mixture in a solvent; c) removing the solvent; and d) drying the mixture. The organic solvent comprises a liposoluble organic solvent such as trichloromethane, dichloromethane, 1,4-dioxane or dimethyl sulfoxide.

4. The method of claim 1, wherein the scaffold material is prepared by the steps of: a) mixing the biocompatible polymer and the bioactive agent; b) dissolving the mixture in a solvent; c) removing the solvent; and d) drying the mixture. The freeze-drying operation comprises freeze-drying treatment in a vacuum drying manner for 48 h.

5. The method of claim 2, wherein the scaffold material is prepared by the steps of: a) mixing the biocompatible polymer and the bioactive agent; b) dissolving the mixture in a solvent; c) removing the solvent; and d) drying the mixture. The preparation method specifically comprises the following steps: dissolving 0.15 g to 0.3 g of gentiopicroside in 1.0 mL of trichloromethane to obtain a gentiopicroside solution; then adding the gentiopicroside solution into 10 g of poly-3-hydroxybutyrate-co-4-hydroxybutyrate solution which has been fully dissolved in 20 mL of trichloromethane; magnetically stirring at room temperature for 1 h to form a uniform solution, and then performing printing by using a biological 3D printer to obtain a porous scaffold crude product; and placing the porous scaffold crude product in a vacuum drying machine for freeze-drying for 48 h to remove trichloromethane, thereby obtaining a GPD@P34HB porous scaffold with a content. 6.A scaffold material for promoting blood vesselization and bone tissue regeneration prepared by the preparation method of the scaffold material for promoting blood vesselization and bone tissue regeneration according to any one of claims 1 to 5. 7.Gentiopicroside as a blood vessel regeneration promoter in the field of preparing a biological scaffold material. 8.Gentiopicroside as a drug in the field of promoting blood vessel regeneration.

9. Use according to claim 8, characterized in that, The preparation method comprises the following steps: 0.356 g of gentiopicroside was placed in a centrifuge tube, 1.0 mL of dimethyl sulfoxide solution was added to the centrifuge tube, and the gentiopicroside was fully dissolved by oscillating on a vortexer for 5 min; then the obtained solution was added dropwise into 9.0 mL of double-distilled water, and filtered by using a 0.22 μm filter membrane to obtain a storage mother liquor with a concentration of 100 mM; The mother liquor was taken and used to prepare human umbilical vein vascular endothelial cell DMEM complete culture media containing gentiopicroside with concentrations of 0, 0.32, 0.64, 1.28 and 2.56 mM, respectively. 10.Gentiopicroside as a therapeutic drug for improving insufficient blood vessel regeneration and related diseases.